Clinical outcomes for rhinovirus-positive visits in comparison with visits positive for other viruses
| Binary outcomes | Rhinovirus | Other viruses combined | OR | 95% CI | p Value |
|---|---|---|---|---|---|
| PEx (%) | 48.6 | 47.8 | 1.10 | 0.60 to 2.06 | 0.740 |
| Prescription of any ABx (%) | 59.4 | 65.2 | 0.92 | 0.46 to 1.83 | 0.808 |
| Prescription of IV ABx (%) | 21.0 | 41.3 | 0.38 | 0.18 to 0.80 | 0.011 |
| Continuous outcomes* | Rhinovirus | Other viruses combined | Adjusted mean difference | 95% CI | p Value |
| URTI score | 7.9 (6.6) | 6.9 (5.6) | +0.96 | −0.96 to +2.89 | 0.328 |
| PEx score | 3.6 (2.4) | 3.6 (2.4) | +0.06 | −0.69 to +0.80 | 0.884 |
| Acute fall in FEV1% | 13.5 (10.7) | 16.9 (11.8) | −2.09 | −5.5 to +1.4 | 0.234 |
| log CRP (mg/l)† | 2.20 (1.4) | 2.21 (1.3) | +0.03 | −0.32 to +0.38 | 0.866 |
| White cell count (×109) | 10.6 (3.9) | 10.3 (3.1) | −0.19 | −0.99 to +0.61 | 0.637 |
Analysis used generalised estimating equation models with logistic regression for binary outcomes and linear regression for continuous variables. Non-rhinovirus viral respiratory infection was the comparator variable in each analysis.
*Continuous variables are reported as mean (SD).
†CRP values were log-transformed to correct for non-normal distribution.
ABx, antibiotics; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; PEx, pulmonary exacerbation; URTI, upper respiratory tract infection.